Eli Lilly And Company ((LLY)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Eli Lilly and Company is conducting a Phase 3 clinical study titled A Master Protocol for a Phase 3, Multicenter, Open-label, Long-term Extension Study to Evaluate the Long-term Efficacy and Safety of Mirikizumab in Children and Adolescents With Moderate-to-severe Ulcerative Colitis or Crohn’s Disease. The study aims to assess the long-term efficacy and safety of Mirikizumab in pediatric patients with these conditions, highlighting its significance in potentially improving treatment options for young patients.
Intervention/Treatment: The study is testing Mirikizumab, a drug administered both subcutaneously and intravenously, intended to treat moderate-to-severe ulcerative colitis and Crohn’s disease in children and adolescents. Different doses are being evaluated based on patient weight, with an option for intravenous rescue dosing if needed.
Study Design: This interventional study is non-randomized with a parallel intervention model, focusing on treatment as its primary purpose. There is no masking involved, meaning both researchers and participants are aware of the treatment being administered.
Study Timeline: The study began on May 26, 2021, and is currently recruiting participants. The last update was submitted on July 22, 2025. These dates are crucial as they indicate the study’s progression and ongoing nature, which is important for tracking its development and potential outcomes.
Market Implications: The update on this study could positively influence Eli Lilly’s stock performance and investor sentiment, as successful results might enhance the company’s portfolio in the pediatric treatment market for ulcerative colitis and Crohn’s disease. The study’s progress may also impact competitors focusing on similar treatments, positioning Eli Lilly strategically in the industry.
Closing Sentence: The study is ongoing, with further details available on the ClinicalTrials portal.